Gastrointestinal Cancer News

Researchers in Japan found that high consumption of alcohol increased the risk for hepatocellular carcinoma among patients with fatty liver disease, according to data from a retrospective cohort study.

Overall survival rates were found to be reduced in patients with esophageal adenocarcinoma who also had the gene mutation tumor protein 53, or TP53, compared with patients with esophageal adenocarcinoma who did not have TP53 as a biomarker. Furthermore, the association existed in patients independent of tumor stage.

Patients with hepatitis C virus infection-related hepatocellular carcinoma who underwent liver transplantation were at an increased risk for developing negative outcomes, such as graft loss and reduced survival, compared with patients with HCC due to other causes, according to published findings.

The presence of BRAF V600E and KRAS mutations appeared associated with shorter DFS and OS in patients with stage III colon cancer and microsatellite-stable tumors, according to post-hoc analysis of a phase 3 randomized trial.

Chemoradiotherapy followed by active surveillance appeared to confer positive outcomes for patients with rectal cancer, according to the results of a matched cohort analysis.

Inflammatory bowel disease patients with a history of cancer who were subsequently exposed to an anti-tumor necrosis factor agent or antimetabolite were not found to have an increased risk for new or recurrent cancer in a recent study.

As part of his State of the Union address, President Barack Obama announced the launch of a national initiative to cure cancer that will be led by Vice President Joe Biden.

In a retrospective cohort study, researchers found that Peruvian patients with advanced-stage hepatocellular carcinoma could undergo liver resection and maintain good outcomes, despite current management guidelines. The researchers suggest that clinicians in developing countries reconsider the guidelines to avoid section bias for treatment.  

Racial and ethnic minority groups in the U.S. are more likely to be diagnosed with colorectal cancer at younger ages and at more advanced stages compared with non-Hispanic whites, according to recent study data.

Nearly half of women cancer survivors continued to experience symptoms of chemotherapy-induced peripheral neuropathy up to 6 years after treatment, according to research presented at the Cancer Survivorship Symposium.